ICIs for HCC: Q&A 2

CME

Immunotherapy for Advanced HCC: Current Options and Expert Answers to Clinician Questions

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: June 29, 2021

Expiration: June 28, 2022

David Kaplan
David Kaplan, MD, MSc
Thomas B. Karasic
Thomas B. Karasic, MD

Activity

Progress
1
Course Completed

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:

  • Current systemic therapy standards of care for patients with advanced HCC
  • Use of single-agent immune checkpoint inhibitor therapy in the first-line setting
  • Assessing bleeding risk
  • Using immunotherapy in patients with active HBV or HCV infections